Senores-new-logo-Oct-2023Senores-new-logo-Oct-2023Senores-new-logo-Oct-2023Senores-new-logo-Oct-2023
  • About Us
    • About Senores
    • Milestone
    • Leadership
    • Partnership
  • Manufacturing
    • Formulations
    • API
  • Products
    • Formulation – Regulated Market
    • Formulation – Emerging Market
    • API
    • Critical Care – Hospital Line
  • R&D
  • Investors
    • Offer Documents
    • Financials
    • Policies
    • Reports
    • Shareholding Pattern
    • Material Creditors
    • Committees
  • Contact

Media

Media Coverage

NOV 2024

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. launches Ivermectin Tablets in the U.S. market (Source: Nasdaq)
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. launches Ivermectin Tablets in the U.S. market (Source: Financial Times)

OCT 2024

Senores Pharmaceuticals gets SEBI's approval to float IPO (Source: Business Standard)

JUL 2024

Senores Pharmaceuticals files DRHP for IPO (Source: The Economic Times)

SEP 2023

Senores Pharmaceuticals, Inc. launches Nicardipine Hydrochloride Capsules (Source: BioSpace)

MAY 2022

Dr. Reddy's and Senores Pharmaceuticals, Inc. launches Ketorolac Tromethamine Tablets (Source: Business Standard)

MAR 2022

Seton Pharmaceuticals, LLC and Senores Pharmaceuticals, Inc. launches Butalbital, Acetaminophen and Caffeine Capsules (Source: TOI)

JAN 2022

Senores Pharmaceuticals, Inc. launches Mexiletine Hydrochloride Capsules (Source: Market Insider)

OCT 2021

Cintex Services, LLC and Senores Pharmaceuticals, Inc. launches Chlorzoxazone Tablets (Source: BioSpace)

NOV 2020

Jubilant Pharma Ltd. and Aavis Pharmaceuticals launches Hydroxychloroquine Sulfate Tablets (Source: Times of India)

Useful Links

  • About Us
  • Manufacturing
  • Products
  • Partnership
  • R&D
  • Regulatory
  • ADR
  • Media
  • Career
  • Contact

Disclaimer

• All the information present on Senores Pharmaceuticals website is not applicable to all the countries across the world. The  purpose  of   this  website is to provide information about Senores Pharmaceuticals' products and services. Any information present on the website shouldn't be misused or construed to spread or promote any of the products in the countries where are disapproved or prohibited.
• Listed  products  in this website will not be supplied to countries in which these could be in conflict with existing valid patents. The buyers should make their independent evaluation of the patent scenario for their respective market as the final responsibility lies exclusively with the buyer.
• Patented products will only be supplied for development, testing, and regulatory submission purposes.

© 2023 Senores Pharmaceuticals | All Rights Reserved.